

# Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, *APOE* $\epsilon$ 4, and Cognitive Impairment

Joseph Therriault, BSc, Tharick A. Pascoal, MD, PhD, Andrea L. Benedet, PhD, et al.

Cite as: *Neurology*® 2021;96:e975-e985. doi:10.1212/WNL.0000000000011416

## Correspondence

Dr. Rosa-Neto

pedro.rosa@mcgill.ca

## Study Question

What is the degree of diagnostic agreement between biologically defined Alzheimer disease (AD) and clinically defined AD?

## What Is Known and What This Paper Adds

A definitive diagnosis of AD has traditionally only been possible at autopsy, but an emerging biological research framework permits the detection of biologically defined AD in living persons. This investigation's results provide evidence for strong but incomplete agreement between the biological and clinical definitions of AD.


## Methods

For this diagnostic test study, the investigators analyzed data from 305 older adults who participated in the Translational Biomarkers for Aging and Dementia study, which occurred through the McGill University in Montréal. Clinicians blinded to neuroimaging data used clinical features to classify the selected participants as being cognitively unimpaired (CU;  $n = 166$ ) or as having amnesic mild cognitive impairment ( $n = 77$ ) or probable AD dementia ( $n = 62$ ). These older adults underwent amyloid- $\beta$  ( $A\beta$ ) PET scans with [ $^{18}\text{F}$ ]-AZD4694 and tau PET scans with [ $^{18}\text{F}$ ]-MK6240. The investigators defined  $A\beta$ -positivity (i.e., A+ status) as having an [ $^{18}\text{F}$ ]-AZD4694 standardized uptake value ratio (SUVR)  $\geq 1.55$  across the neocortex, and they defined tau-positivity (i.e., T+ status) as having an [ $^{18}\text{F}$ ]-MK6240 SUVR  $\geq 1.24$  in a composite of temporal cortical regions. They defined biological AD as being A+T+, in line with the recent framework from the National Institute of Aging-Alzheimer's Association (NIA-AA). The primary outcome was the degree of overlap between cohort members meeting the biological definition of AD and those meeting the clinical definition of AD.

## Results and Study Limitations

The investigators found strong agreement between the biological and clinical definitions of AD, with the 85.2% of people who met the clinical definition of AD also meeting the biological definition. Furthermore, 7.9% of people in

**Figure** Percentages of People With Clinically-Defined Probable AD Dementia Who Were A – T– (Dark Blue), A+T– (Brown), A – T+ (Gray), and A+T+ (Light Blue)



the CU group met the biological definition of AD. These findings are Class I evidence for strong agreement between the biological and clinical definitions of AD. The present study's limitations include the sensitivity–specificity trade-offs inherent to biomarker dichotomization and the study's focus on a recruited cohort, which may limit generalizability to the broader population.

## Study Funding and Competing Interests

This study was funded by the McGill University Faculty of Medicine, the Alzheimer's Society of Canada, the Alzheimer's Association, the Weston Brain Institute, the Brain Canada Foundation, the Fonds de Recherche du Québec—Santé, and the Canadian Institutes of Health Research. The authors report no competing interests. Go to [Neurology.org/N](http://Neurology.org/N) for full disclosures.

*A draft of the short-form article was written by M. Dalefield, a writer with Editage, a division of Cactus Communications. The corresponding author(s) of the full-length article and the journal editors edited and approved the final version.*

# Neurology<sup>®</sup>

## Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, *APOE* $\epsilon$ 4, and Cognitive Impairment

Joseph Therriault, Tharick A. Pascoal, Andrea L. Benedet, et al.  
*Neurology* 2021;96:e975-e985 Published Online before print December 21, 2020  
DOI 10.1212/WNL.0000000000011416

**This information is current as of December 21, 2020**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/96/7/e975.full">http://n.neurology.org/content/96/7/e975.full</a>
<b>References</b>	This article cites 45 articles, 9 of which you can access for free at: <a href="http://n.neurology.org/content/96/7/e975.full#ref-list-1">http://n.neurology.org/content/96/7/e975.full#ref-list-1</a>
<b>Citations</b>	This article has been cited by 1 HighWire-hosted articles: <a href="http://n.neurology.org/content/96/7/e975.full##otherarticles">http://n.neurology.org/content/96/7/e975.full##otherarticles</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>Alzheimer's disease</b> <a href="http://n.neurology.org/cgi/collection/alzheimers_disease">http://n.neurology.org/cgi/collection/alzheimers_disease</a> <b>MCI (mild cognitive impairment)</b> <a href="http://n.neurology.org/cgi/collection/mci_mild_cognitive_impairment">http://n.neurology.org/cgi/collection/mci_mild_cognitive_impairment</a> <b>PET</b> <a href="http://n.neurology.org/cgi/collection/pet">http://n.neurology.org/cgi/collection/pet</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

